<table>
<tr>
<th>Change</th>
<th>Details of Change</th>
<th>Level of Evidence</th>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>Separate N staging approaches have been described for HPV-related and HPV-unrelated cancers.</td>
<td>IT1,2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Separate N category approaches have been described for patients treated without cervical lymph node dissection (clinical N) and patients treated with cervical lymph node dissection (pathological N).</td>
<td>II1,2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Extranodal extension (ENE) is introduced as a descriptor in all HPV- unrelated cancers.</td>
<td>II2</td>
</tr>
<tr>
<td>ENE in HPV-negative cancers</td>
<td>Only clinically and radiographically overt ENE should be used for cN.</td>
<td>II2</td>
</tr>
</table>

To access the AJCC cancer staging forms, please visit www.cancerstaging.org.

<!-- PageFooter="American College of Surgeons 2017 M.B. Amin et al. (eds.), AJCC Cancer Staging Manual, Eighth Edition, DOI 10.1007/978-3-319-40618-3_6" -->
<!-- PageNumber="67" -->
<!-- PageBreak -->
<!-- PageNumber="68" -->
<!-- PageHeader="American Joint Committee on Cancer . 2017" -->

<table>
<tr>
<th>Change</th>
<th>Details of Change</th>
<th>Level of Evidence</th>
</tr>
<tr>
<td>ENE in HPV-negative cancers</td>
<td>Any pathologically detected ENE is considered ENE(+) and is used for pN.</td>
<td>II2</td>
</tr>
<tr>
<td>ENE in HPV-negative cancers</td>
<td>Presence of ENE is designated pN2a for a single ipsilateral node &lt;3 cm and pN3b for all other node(s).</td>
<td>II2</td>
</tr>
<tr>
<td>Classification of ENE</td>
<td>Clinically overt ENE is classified as ENE, and is considered ENE(+) for cN.</td>
<td>III3</td>
</tr>
<tr>
<td>Classification of ENE</td>
<td>Pathologically detected ENE is classified as either ENEmi (≤2mm) or ENEma (&gt;2 mm) for data collection purposes only but both are considered ENE(+) for definition of pN.</td>
<td>III3</td>
</tr>
<tr>
<td>Occult Primary Tumor</td>
<td>Staging of the patient who presents with EBV-unrelated and HPV- unrelated metastatic cervical lymphadenopathy is now included in this chapter.</td>
<td>IV</td>
</tr>
</table>